High proportions of patients have reported neuropathic pain after traumatic nerve injury. [1][2][3] A lesion or disorder of the somatosensory nervous system may result in neuropathic pain 4 which can cause a higher prevalence of sleep disturbances, 5 anxiety, 6 and depression 7 in patients. The prevalence of neuropathic pain has been estimated at around 6.9%-10%. 8 Risk factors for neuropathic pain include demographic, psychological, social/lifestyle, and genetic factors. 9 Post-traumatic peripheral neuropathic pain (PTNP) is defined as chronic neuropathic pain due to damage to peripheral nerves. 10 Some therapeutic interventions have been suggested as treatments for PTNP such as transcutaneous magnetic stimulation, 11 gabapentin, 12 and pregabalin. 13 The potential treatment of pregabalin has been shown in both central and peripheral neuropathic pain. 1,14,15 Some studies showed its efficacy as off-label uses for other conditions such as generalized anxiety disorder, 16 restless legs syndrome, 17 bipolar disorder, 18 and insomnia. 19 Most meta-analyses have been undertaken on the therapeutic value of pregabalin in patients with diabetic peripheral neuropathy (DPN), 20,21 post-herpetic neuralgia (PHN), 22,23 fibromyalgia, 24 and spinal cord injury
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.